Rakuten Medical: A global biotechnology company

We are developing and commercializing precision, cell targeting photoimmunotherapy based on its proprietary Alluminox™ platform.

Our mission:
To **conquer cancer.**

Rakuten Medical
ガン克服。生きる。
CONQUERING Cancer.



Our technology:
Alluminox™ platform



The mission to save my father became a mission to save people.

Mickey Mikitani
CEO, Rakuten Medical, Inc.

Check our history
Article Video

Alluminox™

Alluminox™ platform is
Rakuten Medical's proprietary, precision anticancer photoimmunotherapy technology platform which combines the power of light with drug and device components.



Overview of Therapies based on Alluminox™ Platform

Play our MoA video

Pre-clinical observations

Intravenous Infusion (2 hrs)




Conjugate with IR700

Conjugate binds to targeted cell


24±4hrs after infusion

Illumination



Illumination with 690nm red light activates IR700 on cell-bound conjugate


Necrosis



Rapid and acute cell death through disruption of cell membrane integrity

Ruptured cell releases cancer antigens


Immune Response




Anti-tumor innate and adaptive immunity induced

Pre-clinical data generated at Rakuten Medical


Cell necrosis observed 24 hrs after treatment



CD8+ T cell Frequency in Tumors 7 days post-PIT



Increase in functionally active killer T cells (CD8+ GrB+) in TME at 7 days post-treatment



PIT, photoimmunotherapy; TME, tumor microenvironment; w/o PIT, saline + no illumination

DISCLAIMER: *Rakuten Medical's therapies based on the Alluminox™ platform are investigational outside of Japan.*

Rakuten Medical